Wedbush reiterated its Sangamo BioSciences SGMO Outperform rating and fair value estimate of $9 in a research report published today.
In the report, Wedbush states, "Sangamo has sufficient cash runway through important clinical and strategic milestones in 2012 including Phase 1/2 data for SB-728-T treatment of HIV/AIDS, the initiation of two additional clinical trials of SB-728-T (H1:12), and clarity on a potential clinical candidate from the ZFN program in monogenic diseases."
Shares of Sangamo BioSciences were trading at $2.72 at the time of posting, up 3.38% from Monday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in